At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Anti-pseudomonas IgY gargledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Study of Anti-pseudomonas IgY in Prevention of Recurrence of Pseudomonas Aeruginosa Infections Infections in Cystic Fibrosis (CF) Patients
In Brief
A Phase 2 clinical trial evaluating Anti-pseudomonas IgY gargle for Cystic Fibrosis and 2 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Infection, Pseudomonas Aeruginosa
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
First PostedMar 2008
Primary CompletionDec 2012
TodayJul 2026
First PostedMar 11, 2008
Enrollment StartNov 1, 2003
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 18.3 years ago
Interventions
Anti-pseudomonas IgY gargledrug
Gargle (solution), \> 5FKU, every night after toothbrushing, life-long